

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: GP2/17 - Detection of Monoclonal Components

Dead line: 22.09.2017

Key:	>>> ... marks correct (expected) result	N ... number of the results
	> ... marks conditionally correct (acceptable) result	Nrel ... relative number of the results
	± ... marks the result not evaluated	

Test

Sample	Group	N	Result	N _{rel}	
(246) Gammopathies (typisation)					
A	(12) Beckman Coulter	>>>	1 IgA-kappa; kappa-free	1,1 %	
	(34) Sebia	>>>	50 IgA-kappa	56 %	
		>>>	6 IgA-kappa; kappa-free	6,7 %	
			1 IgA-kappa; kappa-free; lambda-free	1,1 %	
			1 IgM-kappa; IgM-lambda	1,1 %	
	(49) BioVendor	>>>	1 IgA-kappa	1,1 %	
	(100) Helena	>>>	3 IgA-kappa	3,3 %	
	(213) Interlab Srl	>>>	25 IgA-kappa	28 %	
		>>>	2 IgA-kappa; kappa-free	2,2 %	
	----- Total per sample: n = 90 ----- Success: 98 %				
	B	(12) Beckman Coulter	>>>	1 kappa-free	1,1 %
		(34) Sebia		2 Not specified	2,2 %
			>>>	10 kappa	11 %
		>>>	14 kappa; kappa-free	16 %	
		>>>	32 kappa-free	36 %	
(49) BioVendor		>>>	1 kappa-free	1,1 %	
(100) Helena		>>>	1 kappa; kappa-free	1,1 %	
		>>>	2 kappa-free	2,2 %	
(213) Interlab Srl			1 Not specified	1,1 %	
			1 IgG-kappa	1,1 %	
		>>>	7 kappa	7,8 %	
		>>>	5 kappa; kappa-free	5,6 %	
		>>>	13 kappa-free	14 %	
----- Total per sample: n = 90 ----- Success: 96 %					
Total success: 93 %					

st_kl

End of report

Printed: 10.10.2017